erlotinib teva 25 mg filmdragerad tablett
teva sweden ab - erlotinibhydroklorid - filmdragerad tablett - 25 mg - erlotinibhydroklorid 27,32 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne
erlotinib teva 100 mg filmdragerad tablett
teva sweden ab - erlotinibhydroklorid - filmdragerad tablett - 100 mg - erlotinibhydroklorid 109,28 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne
erlotinib ratiopharm 25 mg filmdragerad tablett
ratiopharm gmbh - erlotinibhydroklorid - filmdragerad tablett - 25 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; erlotinibhydroklorid 27,32 mg aktiv substans
erlotinib ratiopharm 100 mg filmdragerad tablett
ratiopharm gmbh - erlotinibhydroklorid - filmdragerad tablett - 100 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; erlotinibhydroklorid 109,28 mg aktiv substans
erlotinib teva 150 mg filmdragerad tablett
teva sweden ab - erlotinibhydroklorid - filmdragerad tablett - 150 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; erlotinibhydroklorid 163,92 mg aktiv substans
erlotinib zentiva 100 mg filmdragerad tablett
zentiva k.s. - erlotinibhydroklorid - filmdragerad tablett - 100 mg - laktosmonohydrat hjälpämne; erlotinibhydroklorid 109,29 mg aktiv substans; natriumlaurilsulfat hjälpämne
erlotinib zentiva 150 mg filmdragerad tablett
zentiva k.s. - erlotinibhydroklorid - filmdragerad tablett - 150 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; erlotinibhydroklorid 163,94 mg aktiv substans
erlotinib zentiva 25 mg filmdragerad tablett
zentiva k.s. - erlotinibhydroklorid - filmdragerad tablett - 25 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; erlotinibhydroklorid 27,32 mg aktiv substans
lorviqua
pfizer europe ma eeig - lorlatinib - carcinom, non-small cell lung - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. se avsnitt 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.